Search / 497 results found

from
to
  • Updated

BEIJING and PHILADELPHIA, Jan. 24, 2022 /PRNewswire/ -- Applied Pharmaceutical Science, Inc. ("APS" or "the Company"), has recently announced the Investigational New Drug (IND) application for its self-developed breakthrough new drug APS03118, a next generation selective RET inhibitor, has been approved by the U.S. Food and Drug Administration (FDA). The clinical application is also in the process of being submitted to the National Medical Products Administration (NMPA) in China, and a global multi-center clinical trial is in the pipeline for initiation in the second quarter of 2022 in the U.S., China and Australia etc.

  • Updated

BEIJING and PHILADELPHIA, Jan. 23, 2022 /PRNewswire/ -- Applied Pharmaceutical Science, Inc. ("APS" or "the Company"), has recently announced the Investigational New Drug (IND) application for its self-developed breakthrough new drug APS03118, a next generation selective RET inhibitor, has been approved by the U.S. Food and Drug Administration (FDA). The clinical application is also in the process of being submitted to the National Medical Products Administration (NMPA) in China, and a global multi-center clinical trial is in the pipeline for initiation in the second quarter of 2022 in the U.S., China and Australia etc.

  • Updated

BEIJING and PHILADELPHIA, Jan. 23, 2022 /CNW/ -- Applied Pharmaceutical Science, Inc. ("APS" or "the Company"), has recently announced the Investigational New Drug (IND) application for its self-developed breakthrough new drug APS03118, a next generation selective RET inhibitor, has been approved by the U.S. Food and Drug Administration (FDA). The clinical application is also in the process of being submitted to the National Medical Products Administration (NMPA) in China, and a global multi-center clinical trial is in the pipeline for initiation in the second quarter of 2022 in the U.S., China and Australia etc.

Late last year, at 3 a.m. in what is a now-normal night, Kim Hoffman awoke with "an unbelievable headache." These are related to the 30 brain lesions, and the steroids needed to reduce the swelling of the brain. After dawn that day, she said, speaking by phone from her home in Glastonbury, Connecticut, "I felt a new neck lesion." She has so many skin lesions that "it feels as though my skin is being torn like someone has a serrated knife."

As fatal overdose numbers throughout Cambria County continued to climb during the COVID-19 pandemic, the Cambria County Drug Coalition was determined to make changes. As an agency, we recognized that this would require collaboration from trusted partners as well as a detailed review of the individual lives lost.

  • Updated

SILVER SPRING, Md., Jan. 21, 2022 /PRNewswire/ -- Today, the U.S. Food and Drug Administration took two actions to expand the use of the antiviral drug Veklury (remdesivir) to certain non-hospitalized adults and pediatric patients for the treatment of mild-to-moderate COVID-19 disease. This provides another treatment option to reduce the risk of hospitalization in high-risk patients. Previously, the use of Veklury was limited to patients requiring hospitalization.

  • Updated

Here is what the editors at Physician's Briefing chose as the most important COVID-19 developments for you and your practice for the week of Jan. 17 to 21, 2022. This roundup includes the latest research news from journal studies and other trusted sources that is most likely to affect clinical practice.

  • Updated

NORTH CHICAGO, Ill., Jan. 21, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts approximately 30 percent of patients with psoriasis.1,4-7